New drug cocktail shows promise against tough blood cancer
NCT ID NCT01661881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-step drug combination for people newly diagnosed with mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. Twenty-three patients who were eligible for a stem cell transplant received rituximab and bendamustine followed by rituximab and cytarabine. The goal was to see if this approach could improve the number of patients achieving complete remission before their transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
23 people
The number who actually took part.
- Started
-
Aug 2012
- Expected to finish
-
Apr 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 69 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Mandatory pathologic review of the diagnostic specimen(s) at Brigham and Women's Hospital or Massachusetts General Hospital * Measurable disease * Candidate for ASCT Exclusion Criteria: * Prior anti-lymphoma therapy * Pregnant or breastfeeding * Hypersensitivity to rituximab * Uncontrolled intercurrent illness * Receiving other study agents * HIV positive on combination antiretroviral therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mantle cell lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
- Triple drug combo targets mantle cell lymphoma
- New drug joins standard chemotherapy in fight against B-Cell lymphoma
- Which lymphoma drug combo works best? a new study aims to find out
- Can a Three-Drug combo erase mantle cell lymphoma without chemotherapy?
- Can a single injection reprogram immune cells to fight cancer?